In a report released today, Martyn Jacobs from Bell Potter maintained a Buy rating on Integral Diagnostics Ltd., with a price target of A$3.15.
Jacobs covers the Healthcare sector, focusing on stocks such as Lumos Diagnostics Holdings Ltd., Artrya Limited, and Sonic Healthcare Limited. According to TipRanks, Jacobs has an average return of -15.6% and a 23.18% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Integral Diagnostics Ltd. with a A$3.08 average price target.
Based on Integral Diagnostics Ltd.’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of A$393.48 million and a net profit of A$8.96 million. In comparison, last year the company earned a revenue of A$252.87 million and had a GAAP net loss of A$396 thousand
Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of IDX in relation to earlier this year.
